Kyowa Kirin International (KKI) has announced the upcoming presentation of interim findings from three significant real-world studies focusing on cutaneous T-cell lymphoma (CTCL) at the European Organisation for Research and Treatment of Cancer’s Cutaneous Lymphoma Tumour Group (EORTC-CLTG) annual meeting. The event is set to take place in Lausanne, Switzerland, from 9 to 11 October 2024.
These studies involve participants from Europe, the United States, and the United Arab Emirates, and aim to gather evidence regarding the effectiveness of mogamulizumab, a pioneering humanised monoclonal antibody therapy. This treatment is currently approved in Europe and the UAE for adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have undergone at least one prior systemic therapy. In the US and Switzerland, mogamulizumab is also approved for adult patients with relapsed or refractory MF or SS.
Professor Emmanuella Guenova, Chief Physician of Dermatology and Venereology at Lausanne University Hospital and Chair of the EORTC-CLTG 2024 Annual Meeting, emphasised the importance of real-world evidence in guiding treatment decisions. “For most patients, treatment of CTCL aims to prolong time to disease progression, reduce the burden of disease, and preserve or enhance quality of life,” she noted. “The data being established by Kyowa Kirin is invaluable for physicians in understanding treatment responses in real-world settings.”
This presentation will showcase the second interim analyses from three ongoing studies:
- MINT (conducted in Germany) and MIBERIC (Spain and Portugal) are focused on evaluating the effectiveness and tolerability of mogamulizumab in clinical practice. The findings thus far align with the efficacy and safety data observed in global clinical trials, with no new safety signals reported across both studies.
- PROSPER, which includes participants from the US, UAE, Spain, Italy, the Netherlands, and the UK, investigates the impact of mogamulizumab from the patient’s perspective. The study assesses various symptoms and health-related quality of life (HRQoL), highlighting significant improvements in skin symptoms—including pain, itch, flaking, and redness—within four weeks of treatment. Moreover, improvements in patient-reported fatigue and overall HRQoL were reported within 24 weeks.
Dr Nicholas Kronfeld, Senior Vice President and Head of Medical Affairs at Kyowa Kirin International, stated, “The studies being presented at EORTC-CLTG build on our previous presentations and reinforce our commitment to providing the community with comprehensive real-world data. This will enhance clinical decision-making and aim to improve patient outcomes.”
Kyowa Kirin is dedicated to sharing scientific knowledge at the EORTC-CLTG 2024 meeting, with three accepted abstracts scheduled for presentation.
The presentations will include:
- MINT Study: “Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: Update on the German non-interventional MINT study,” presented by Prof. Chalid Assaf on 9 October.
- MIBERIC Study: “Real-world effectiveness of mogamulizumab in Spain and Portugal: Second interim analysis,” presented by Prof. Pablo Ortiz Romero on 9 October.
- PROSPER Study: “Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results,” presented by Prof. Julia Scarisbrick on 10 October.
For further details about Kyowa Kirin and its research, visit Kyowa Kirin’s website.